NCT05883449 2025-08-20
LuminICE-203
Affimed GmbH
Phase 2 Terminated
Clinical Trials
10 trialsNCT00994643 2025-04-30
Safety and Efficacy Study of Immunotherapy With Rituximab and Interleukin-2 in Patients With Non-Hodgkin's Lymphoma
Thomas Jefferson University
Phase 2 Completed
NCT00101101 2023-08-22
Universal Granulocyte Macrophage-colony Stimulating Factor (GM-CSF)-Producing and GM.CD40L for Autologous Tumor Vaccine in Mantle Cell Lymphoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT01700946 2022-09-28
Therapy for Pediatric Relapsed or Refractory Precursor B-Cell Acute Lymphoblastic Leukemia and Lymphoma
St. Jude Children's Research Hospital
Phase 2 Completed
NCT00539695 2018-05-04
IL2 for GVHD
Baylor College of Medicine
Phase 2 Completed
NCT01181258 2018-02-06
MT2009-15
Masonic Cancer Center, University of Minnesota
Phase 2 Completed
NCT02259348 2017-05-30
Repeat Transplantation for Relapsed or Refractory Hematologic Malignancies Following Prior Transplantation
St. Jude Children's Research Hospital
Phase 2 Terminated
NCT00941928 2014-05-22
Haploidentical Natural Killer (NK) Cells With Epratuzumab for Relapsed Acute Lymphoblastic Leukemia (ALL)
M.D. Anderson Cancer Center
Phase 2 Terminated
NCT00001430 2008-03-04
A Randomized Study of EPOCH II Versus EPOCH II and Immunotherapy in Lymphomas
National Institutes of Health Clinical Center (CC)
Phase 2 Completed
NCT00100737 2006-02-06
Comparing Interleukin-2 (IL-2) Combined With Rituximab (Rituxan) to Rituximab Alone in Subjects With Non-Hodgkin's Lymphoma (NHL)
Chiron Corporation
Phase 2 Terminated